A laboratory compound built to prove a point about how selegiline works, never given to a person in any published study. Rats learned faster and resisted chemically induced apathy, but no human dose and no safety record exist. Its proposed mechanism remains contested, and independent testing places it among ordinary stimulants. (Full Review)

Protocol

No established human protocol

No dose, schedule, or duration

Never given to a person in a published study; no clinic or guideline uses it.

Animal reference dosing

1–5 mg/kg in rodents

Subcutaneous; motility rose at 2 mg/kg. Human scaling is not reliable; no allometric conversion published.

Best time of day

Morning only

Evening dosing predicted to impair sleep onset. No chronopharmacology study exists.

Time to effect

Unknown in humans

No human onset, duration, or steady-state timing has been measured.

Behavioural effect in rodents

Within a single session

Suggesting acute rather than cumulative action.

Transmitter release in rodents

30 minutes

Transmitter-release change measured after injection in rodents.

Benefits

Speculative: Learning and retention facilitation; resistance to chemically induced motivational loss; antidepressant-type behavioural activity; wide effective dose range without repetitive behaviour; protection of brain cells against oxygen deprivation; geroprotection

Contraindications

Monoamine oxidase inhibitors, or within 14 days of stopping an irreversible one

Uncontrolled hypertension (seated blood pressure ≥160/100 mmHg)

Coronary artery disease, myocardial infarction (<12 months), or tachyarrhythmia

Heart failure, New York Heart Association Class III or IV (marked limitation, or symptoms at rest)

Structural cardiac disease, or family history of sudden cardiac death before age 50

History of psychosis, schizophrenia, or bipolar I disorder

History of stimulant, cocaine, or methamphetamine use disorder

Seizure disorder, narrow-angle glaucoma, or untreated hyperthyroidism

Moderate or severe hepatic impairment (Child-Pugh Class B or C)

Pregnancy, planned pregnancy, or breastfeeding

Age under 25

Key Interactions

Serotonergic antidepressants (sertraline, venlafaxine, tricyclics)

Other stimulants (amphetamine, methylphenidate, modafinil, high-dose caffeine)

Sympathomimetic (adrenaline-mimicking) over-the-counter medicines (pseudoephedrine, phenylephrine, oxymetazoline)

Stimulant supplements (yohimbine, synephrine, higenamine, caffeine-plus-theanine pre-workouts)

Additive dopaminergic supplements (L-Tyrosine, levodopa-containing Mucuna pruriens, β-phenylethylamine)

CYP-inhibiting agents (fluoxetine, paroxetine, bupropion, ritonavir, grapefruit juice)

Anaesthesia and surgery

Risk & Side Effects

Speculative: Sympathetic cardiovascular stimulation; sleep disruption and overstimulation; psychosis, mania, and severe agitation; abuse and dependence liability; altered peripheral immune-cell serotonin; behavioural suppression and toxicity at high doses

Monitoring

Marker	Target	Why
Seated blood pressure	110–125 / 65–80 mmHg	Earliest sign of sympathetic overstimulation
Resting heart rate	50–65 bpm	Tracks adrenergic load and cardiac strain
Corrected QT interval (QTc)	<440 ms (men), <450 ms (women)	Detects stimulant-class arrhythmia risk
Alanine aminotransferase (ALT)	10–25 U/L (men), 8–20 U/L (women)	Clearance route unmapped; liver stress
Serum prolactin	4–15 ng/mL (men), 4–23 ng/mL (women)	Falls when central dopamine signalling rises
Thyroid-stimulating hormone	0.5–2.0 mIU/L	Excludes hyperthyroidism, which mimics stimulant effects
Fasting glucose	75–90 mg/dL	Catecholamine elevation opposes insulin action
Body weight	None; track change from baseline	Appetite suppression shows first as weight loss

Cadence: Blood pressure and heart rate twice daily for two weeks, then weekly. Electrocardiogram at four weeks; liver panel and blood count at eight weeks, then every three to six months.

Qualitative Assessment

Sleep quality: Time to fall asleep, night wakings, restorative feel; earliest warning sign.
Cognitive clarity: Sustained attention, working-memory slips, word-finding, against the pre-exposure record.
Energy and drive: Willingness to begin effortful tasks, distinct from restlessness or agitation.
Mood and irritability: Emotional range, frustration tolerance, flattening or edginess noticed by others.
Appetite: Meals skipped without hunger, an early nutritional marker.

Phenylpropylaminopentane for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment